Welcome to CIMED
CIMED pioneered a novel Soft-targeting Polymolecular Strategy Designed to intercept, slow down, or reverse chronic disease progression. CIMED’s goal is to avoid the need for lifelong dependence on synthetic drugs and avoid complications linked to chronic disease. CIMED’s goal is to optimize the potential of lifestyle modification and regenerative medicine solutions. CIMED’s mission is to enable healthy living and aging.
CIMED’s patentable polymolecular, dose-standardized, and naturally derived therapeutic products soft-target multiple molecular pathways to avoid toxicity and problems associated with the hard-targeting, fast-acting synthetic molecules. In addition, the CIMED science of transforming food into a vehicle for inducing gradual but significant medical benefits produces the least disruption to normal physiological processes and empowers the natural healing processes of the body to “intercept” chronic disease.
The second area of R&D focus of CIMED is the orphan areas of medicine where currently there is no standard of care treatment available.
Who we are:
Established in 2018, Composite Interceptive Med-Sciences Laboratories Private Limited (CIMED) is an R&D company based out of Bangalore, the IT & Biotech Capital of India. We are a unique R&D enterprise specializing in a new genre of Interceptive Medicine Therapeutics bringing together physicians, chemists, molecular biologists, engineers, and traditional medicine experts for engineering novel strategies to intercept the progression of chronic diseases. We also work on other orphan areas of medical therapeutics where current strategies of management have proven inadequate or are absent.
CIMED is one of the first companies to work towards creating a composite pharmacology that can create Interceptive Medicine. It will be the first to put into practice, the knowledge of genetic predisposition to disease and help the individual to intercept or delay the onset or progression of diseases using CIMED drugs.
What we are All about:
We are committed to creating a paradigm shift in health care where diseases are targeted along its continuum before their manifestation as a diagnosable disease. Our approach is not to replace the current pharmaceutical standard of care, but to optimize clinical outcomes using our scientifically validated Interceptive medicines.
How we do it:
By modeling disease processes and exploring diverse approaches to leveraging specific clinical outcomes, combining diverse drug development strategies adopting, repurposing and creating new strategies from both allopathic as well as traditional systems of medicine with application of Artificial Intelligence (AI) to model and engineer solutions. At CIMED our proprietary In-Silico machine learning algorithm integrates genomic sequencing data with emerging knowledge on pathophysiology of disease chronic states, applying it to the current rationale of pharmaceutical research and exploration of different systems of medicine. Decades of clinical experience of our core scientific team having access to diverse clinical data helps make creative impactful decisions to fast track discovery.